Department of Nuclear Medicine, Faculty of Medicine, Gazi University, Ankara, Turkey
Department of Neurology, Faculty of Medicine, Gazi University, Ankara, Turkey
Turk J Med Sci. 2021 Apr 30;51(2):400-410. doi: 10.3906/sag-2008-253.
The dopamine transporter (DAT) imaging provides an objective tool for the assessment of dopaminergic function of presynaptic terminals which is valuable for the differential diagnosis of parkinsonian disorders related to a striatal dopaminergic deficiency from movement disorders not related a striatal dopaminergic deficiency. DAT imaging with single-photon emission computed tomography (SPECT) can be used to confirm or exclude a diagnosis of dopamine deficient parkinsonism in cases where the diagnosis is unclear. It can also detect the dopaminergic dysfunction in presymptomatic subjects at risk for Parkinson’s disease (PD) since the reduced radiotracer binding to DATs in striatum is already present in the prodromal stage of PD. This review covers the rationale of using DAT SPECT imaging in the diagnosis of PD and other parkinsonian disorders, specifically focusing on the practical aspects of imaging and routine clinical indications.
多巴胺转运体（DAT）成像为评估突触前末梢多巴胺能功能提供了一种客观工具，对于鉴别与纹状体多巴胺缺乏相关的帕金森病障碍与不相关的运动障碍具有重要价值。单光子发射计算机断层扫描（SPECT）的 DAT 成像可用于在诊断不明确的情况下确认或排除多巴胺缺乏性帕金森病的诊断。由于纹状体中放射性示踪剂与 DAT 的结合减少已经存在于帕金森病（PD）的前驱期，因此它还可以检测处于帕金森病风险的无症状受试者的多巴胺能功能障碍。这篇综述涵盖了使用 DAT SPECT 成像诊断 PD 和其他帕金森病障碍的基本原理，特别侧重于成像的实际方面和常规临床适应症。
